Graybug Vision Concludes Patient Enrollment in its Phase 2b Clinical Trial of GB-102 in Wet Age-Related Macular Degeneration and Accelerates Trial Read-out by Approximately Six Months

NEXT STORY
NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer
PREV STORY
VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATE
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Inivata: Announces Strategic Partnership with Levine Cancer Institute and Formation of the Inivata Knowledge Accumulation Network

Inivata Announces Strategic Partnership with Levine Cancer Institute and Formationof the Inivata Knowledge Accumulation ...

author_avatar
NASDAQ Market News

Horizon Pharma plc to Host Second-Quarter 2017 Conference Call and Webcast on Aug. 7, 2017

DUBLIN, Ireland, July 10, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical ...

author_avatar
NASDAQ Market News

Antiulcerant Drugs to Escalate in Emerging Markets to 2022

Technology advances, unhealthy lifestyles propel global marketWELLESLEY, Mass., June 06, 2018 (GLOBE NEWSWIRE) -- ...

author_avatar
NASDAQ Market News